NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NASDAQ NURO opened at $3.97 on Wednesday. The company has a market cap of $8.10 million, a P/E ratio of -0.86 and a beta of 2.29. NeuroMetrix has a 1 year low of $2.66 and a 1 year high of $4.73. The firm has a 50-day simple moving average of $4.03 and a two-hundred day simple moving average of $3.84.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. During the same period in the prior year, the firm posted ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.